Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort
Carina Mihai(Carol Davila University of Medicine and Pharmacy), Dorota Krasowska(Medical University of Lublin), Ulrich A. Walker(University Hospital of Basel), Paul I Constantin(Carol Davila University of Medicine and Pharmacy), Iulia Szabo, Jörg Henes(University of Tübingen), Fabio Cacciapaglia, Florenzo Iannone(University of Bari Aldo Moro), Alexandra Balbir‐Gurman(Technion – Israel Institute of Technology), É. Hachulla(Centre Hospitalier Universitaire de Lille), Duška Martinović(University of Split), Carlomaurizio Montecucco(University of Pavia), Vanessa Smith(Ghent University Hospital), Rucsandra Dobrota(University of Zurich), Paolo Airó(University of Lisbon), Paola Caramaschi(University of Verona), Tünde Minier, Marco Matucci‐Cerinic(Vita-Salute San Raffaele University), Simona Rednic(Charité - Universitätsmedizin Berlin), Nicolas Hunzelmann(University Hospital Cologne), Yannick Allanore(Inserm), Suzana Jordan(University of Zurich), Andrea Doria(University of Padua), Jadranka Morović‐Vergles, Roberto Caporali(University of Milan), Gemma Lepri, Ana Maria Gheorghiu, Elise Siegert(Humboldt-Universität zu Berlin), Stefan Heitmann(Marienhospital Stuttgart), Michal Tomčík(Institute of Rheumatology), Oliver Distler(University Hospital of Zurich), Patrícia Carreira, Veronica Codullo(Université de Strasbourg), Radim Bečvář(Charles University), Yolanda Braun‐Moscovici(Rambam Health Care Campus), Carlo Chizzolini(University of Geneva), Maria Grazia Lazzaroni(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Mislav Radić, Veronika K. Jaeger, Elisabetta Zanatta(University of Padua), Beatriz Ioven, László Czirják(University of Pecs), Christopher Denton, Danièle Allali, Ana Petcu, Serena Vettori, Ulf Müller-Ladner, Vera Ortiz-Santamaría
Cited by 29
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
|Annals of the Rheumatic Diseases|2012|1k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
|New England Journal of Medicine|2009|857